Navigation Links
Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:9/9/2009

THE WOODLANDS, Texas, Sept. 9 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Morgan Stanley Global Healthcare Unplugged Conference at the Grand Hyatt hotel in New York, New York on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other ma
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
2. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
3. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
4. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
5. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
6. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
7. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
8. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
9. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
10. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Calif. (PRWEB) , ... July 02, 2015 , ... Sleepless ... improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound ... Luzi's voice command technology makes it effortless to use, while the integration of the ...
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... Agendia BV, a,world leader in the rapidly evolving field ... Officer Laura van ,t Veer has,received a prestigious 2007 ... Cancer Research Foundation. The Pink Ribbon ,Breast Cancer ... breast cancer researchers with a total value of,32 M$. ...
... Oximetry Unit, NEW YORK, Oct. 22 SPO ... biosensor and microprocessor,technologies for use in portable monitoring devices, ... unit. This sales milestone has,been achieved within three years ... The bulk of the 100,000 units sold include the ...
... Holdings Asia and,its co-investors today announced that they ... the world,s largest privately held,crop- protection and life-science ... billion (US$2.2 billion). The sale will culminate a,five-year ... private,equity firm with investment teams in Japan, Greater ...
Cached Biology Technology:Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award 2SPO Medical Announces Major Sales Milestone 2SPO Medical Announces Major Sales Milestone 3Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... in which the aging process is linked to DNA damage--which ... influences--and the various ways in which cells repair that damage. ... fruit flies make use of a different mix of molecular ... are reported by William Engels and colleagues at the University ...
... “vile and cynical exploitation?by the alternative medicines industry, argues a ... that up to 80% of all patients with cancer take ... treat their cancer, writes Jonathan Waxman, Professor of Oncology at ... use of many of these approaches is obtuse ?one might ...
... The widely used breast cancer drug tamoxifen (Nolvadex®), which ... full strength indefinitely if used along with a second ... investigators from the National Cancer Institute (NCI), part of ... results appear in the December 11, 2006, issue of ...
Cached Biology News:Age-related changes in DNA repair illuminate the connection between age and genetic damage 2Protect patients from exploitation by alternative medicines industry 2Restoring tamoxifen sensitivity in resistant breast cancer cells 2